Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

myRocky vs Believe Health

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #525

myRocky

Cost-first shoppers who want the real FDA-approved branded pens (not a compounded copy), for shoppers willing to pay branded-drug prices.

Visit myRocky
VS
Grade C · #528

Believe Health

Readers who want the peptide catalog and are prepared to complete an intake before learning what a GLP-1 costs.

Visit Believe Health

The verdict

Winner · myRockyGrade C vs C

myRocky takes it, leading the Cost-Efficiency Index 38 to 37. myRocky is a US-facing telehealth platform selling only branded GLP-1s Ozempic ($1,409 listed), Wegovy ($1,869 listed), and Mounjaro ($1,509 listed) dispensed by LegitScript-approved MyRocky Pharmacy (license #308582). Believe Health still earns a CReaders who want the peptide catalog and are prepared to complete an intake before learning what a GLP-1 costs.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs myRocky.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

22
45

Price Transparency

20
20

Nationwide Access

24
24

Formulation Options

79
40

Clinical Oversight

65
60

Contract Flexibility

41
39

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecmyRockyBelieve Health
Cost-Efficiency Index38/10037/100
Semaglutide / mo$1,409/mo (brand Ozempic, plus a separate fee)Not disclosed
Tirzepatide / mo$1,509/mo (brand Mounjaro, plus a separate fee)Not disclosed
Semaglutide / yr (modeled)$16,908
Tirzepatide / yr (modeled)$18,108
CoverageCoverage not publishedCoverage not published
Oral / sublingualNoNo
Brand-name accessYesCompounded only
Rank here#525#528

myRocky

38/100

Where the value is

  • Sells only genuine FDA-approved branded medications (Ozempic, Wegovy, Mounjaro) rather than compounded copies — a real differentiator from most of the other sites in this batch
  • LegitScript-approved pharmacy, publishing the number #308582 beside that claim (we could not resolve it as a LegitScript seal ID in August 2026; it may be a pharmacy license number, which that registry would not serve)
  • Explicit 42-state coverage list published on a dedicated service-coverage page, with 8 more states named as 'coming soon' — more specific than most peers' vague language

The tradeoffs

  • Pricing is split across a $99 consult, a separate $99/month program fee, and the drug cost itself — a shopper reading only '$99/month' would badly underestimate the real all-in cost
  • None of the three drug-specific pages (Ozempic $1,409, Wegovy $1,869, Mounjaro $1,509) discloses whether that figure is a one-month or multi-month supply
Visit myRocky

Full myRocky review →

Believe Health

37/100

Where the value is

  • Publishes a full peptide catalog with 19 priced entries before any intake, while publishing no GLP-1 price at all
  • Names its operating company, Believe Health LLC, in terms updated in June 2026 — the August record found no entity at all
  • States plainly that you are charged only after a physician approves a plan

The tradeoffs

  • No GLP-1 price is published anywhere — every treatment page reads "AVAILABLE BY CONSULTATION" where a figure would sit, while the same pages promise "flat-rate pricing and no hidden fees"
  • The low-dose GLP-1 is sold without naming its molecule on any page
Visit Believe Health

Full Believe Health review →

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons